Halozyme Therapeutics, Inc. (HALO) Cash Flow Statement

The OCF/NI ratio has been consistently above 1.0 in recent quarters, except for 2025Q2 and 2024Q2 where it dipped to 0.60, suggesting temporary working capital drags. The 2025Q4 net loss of $141.6M was driven by a non-cash charge, as operating cash flow remained positive at $219.0M, underscoring that the loss did not reflect cash generation. This divergence between net income and operating cash flow in 2025Q4 appears to be a one-time event, but investors should monitor whether such charges recur.

FCF has grown from $53.2M in 2024Q2 to $236.7M in 2026Q2, with margins improving from 23.0% to 49.2%, indicating a structural shift in cash generation. The trajectory is supported by revenue acceleration and stable capex, which remains minimal at under 1% of revenue. This robust FCF growth appears sustainable given the royalty-based model, though it is inherently tied to partner product performance.

Capex has never exceeded $4.2M in a quarter, even as revenue grew to $481.0M, indicating that Halozyme's infrastructure is largely outsourced or partner-funded. This low capital intensity allows nearly all operating cash flow to convert to free cash flow, a key competitive advantage versus traditional biotech manufacturers. However, this also implies reliance on third-party manufacturing capacity, which could become a bottleneck if partner volumes scale unexpectedly.

The negative working capital changes in several quarters (e.g., -$62.3M in 2025Q2) suggest that receivables build-up or payables timing can cause temporary cash flow dips, but these have reversed in subsequent quarters. The positive $26.2M in 2026Q2 indicates a net release of cash from working capital, which may reflect improved collection efficiency. Investors should expect continued quarter-to-quarter volatility in working capital due to the lumpy nature of royalty payments from partners.

Buybacks have been intermittent but significant, with $300.2M in 2025Q2 and $250.0M in 2024Q4, suggesting management uses excess cash to repurchase shares opportunistically. The $1.0B acquisition outflow in 2025Q4 aligns with the net loss that quarter, indicating a major strategic investment that may enhance future royalty streams. Despite these outflows, cash flow remains robust, and the balance sheet appears healthy, but investors should monitor the return on these deployed funds.

The cumulative OCF/NI ratio of 1.36 suggests that Halozyme's earnings quality is high, with cash conversion benefiting from non-cash charges like D&A and SBC. The gap is partly due to the 2025Q4 non-cash loss, which reduced net income but not cash flow. This divergence supports the view that the company's profitability is not overstated, and the cash flow statement confirms the sustainability of its earnings power.